Clémentine S.
- Country
- France
- Department
- Oncologie
Research Overview
- Phase 1 Study of JNJ-80948543, a T-cell Redirecting Antibody, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Phase 1 Evaluation of PRT2527 Monotherapy and Combination with Zanubrutinib or Venetoclax in Relapsed/Refractory Hematologic Malignancies
- A Phase 1 Study of IM-1021 in Participants with Advanced Solid Tumors and Advanced B-cell Lymphomas
Data & Insights
Has run more than one trial at 160 of 365 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating various forms of B-cell lymphomas, with particular focus on Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma. Their research encompasses both newly diagnosed and advanced-stage cases.
- High-risk Mantle Cell Lymphoma
- Advanced Stage Follicular Lymphoma
- Large B-cell Lymphoma
The investigator conducts research on innovative therapeutic combinations for lymphoma treatment, including targeted therapies and immunotherapy approaches.
Leukemia Studies
Their expertise extends to various forms of leukemia, particularly focusing on Chronic Lymphocytic Leukemia (CLL) and related conditions. The investigator studies both conventional and novel therapeutic approaches.
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acute Myeloid Leukemia
Research interests include investigating new therapeutic agents and combination treatments for hematologic malignancies.
Blood Cancer Therapeutics
The investigator works with novel therapeutic approaches for blood cancers, including T-cell redirecting antibodies and innovative drug combinations.
- B-cell Malignancies
- Myelodysplastic Syndrome
- Marginal Zone Lymphoma
Their research encompasses evaluating new treatment modalities and investigating therapeutic combinations for various hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.